Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders [Accessibility Statement] Skip NavigationMILWAUKEE, Feb. 23, 2026 /PRNewswire/ -- Ademi LLP is investigating Arcellx (NASDAQ: ACLX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Leonard Green & Partners.Click [here] to learn how to join our investigation and obtain additional information or contact us at [[email protected]] ...

联合航空跌1.7%、美国航空跌1.1%、达美航空跌1.5%，受特大暴风雪影响，航空公司被迫在全美范围 内取消航班。Arcellx涨78.1%，吉利德科学将以每股115美元的价格收购Arcellx。诺和诺德跌15.6%，其 减肥药CagriSema试验效果不及礼来的竞品，礼来涨4.8%。达美乐披萨涨6.0%，Q4营收超预期。 来源：滚动播报 ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Baird upgraded Henry Schein (HSIC) to Outperform from Neutral with a price target of $100, up from $78. The firm believes the bias across its dental names remains to the upside.UBS upgraded BlackRock (BLK) to Buy from Neutral with a $1,280 price target. The upgrade is supported by strong Q4 results, positive comme ...

Core Viewpoint - Arcellx's stock surged approximately 80% following Gilead Sciences' announcement to acquire the cancer-therapy developer for $7.8 billion in an all-cash deal, with a definitive buyout price set at $115 per share [1]. Deal Structure - Gilead will pay $115 per share in cash, plus a contingent value right (CVR) worth an additional $5 per share if Arcellx's lead therapy, anito-cel, achieves at least $6 billion in cumulative global net sales by the end of 2029 [1]. - The total offer represents a premium of about 87% over Arcellx's previous closing price, prompting immediate trading activity towards the buyout price [1]. - The transaction is structured as a tender offer followed by a second-step merger, already approved by both companies' boards [1]. Strategic Importance - Gilead is acquiring anitocabtagene autoleucel (anito-cel), a CAR-T therapy for relapsed or refractory multiple myeloma, which presents a significant commercial opportunity despite intense competition from established products like Johnson & Johnson's Carvykti [1]. - Analysts have previously noted supportive data for anito-cel's potential, with comparisons to Carvykti as the datasets have matured [1]. - The FDA is expected to make a decision on anito-cel by December 23, 2026, which positions the acquisition within a near-launch timeframe rather than a distant research phase [1]. Historical Context - Gilead and Arcellx have collaborated in cell therapy since 2022, making this acquisition a consolidation of a program that Gilead is already familiar with [1].

微信编辑 | 格蕾丝 2月23日，吉利德科学公司表示，拟78亿美元收购癌症细胞疗法公司Arcellx。该消息宣布后，Arcellx股 价上涨近80%。此前，吉利德科学公司旗下Kite Pharma与Arcellx合作，共同开发并销售一种用于多发性 骨髓瘤的实验性CAR-T疗法。 ...

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Logos of Gilead at the company's booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov [Purchase Licensing Rights, opens new tab]- Companies[Arcellx Inc]Follow[Gilead Sciences Inc]FollowFeb 23 (Reuters) - Gilead Sciences will pay as much as $7.8 billi ...

Core Viewpoint - Halper Sadeh LLC is investigating the sale of Arcellx, Inc. to Gilead Sciences, Inc. for $115.00 per share in cash, plus a contingent value right of $5.00 per share based on certain milestones [1] Group 1: Investigation Details - The investigation focuses on whether Arcellx and its board violated federal securities laws and/or breached fiduciary duties by failing to obtain the best possible price for shareholders [2] - Concerns include the fairness of the sales process and potential conflicts of interest, as well as the adequacy of disclosed material information for shareholders to evaluate the transaction [2] Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits on behalf of shareholders [3] - The firm represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [3]

交易完成后，吉利德将为每股支付 115 美元现金，外加每股 5 美元的或有价值权，这一报价较 Arcellx 上一交易日收盘价溢价 87%。 来源：环球市场播报 吉利德科学周一宣布，将以 78 亿美元的股权价值收购癌症疗法研发公司 Arcellx。该消息推动 Arcellx 股价在盘前交易中大涨 77.8%，至 113.99 美元。 ...

Core Insights - Gilead Sciences has agreed to acquire the remaining stake in development partner Arcellx, valuing the biotechnology company at approximately $7.8 billion upon closing [1] Company Summary - The acquisition signifies Gilead Sciences' commitment to expanding its portfolio in the biotechnology sector [1] - Arcellx is positioned to enhance Gilead's capabilities in developing innovative therapies [1]

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.By [Callum Keown]ShareResize---ReprintsIn this ...